Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.67 USD | -0.68% | -5.20% | -22.97% |
Financials (USD)
Sales 2024 * | 29.08M | Sales 2025 * | 2.68M | Capitalization | 834M |
---|---|---|---|---|---|
Net income 2024 * | -199M | Net income 2025 * | -297M | EV / Sales 2024 * | 10.5 x |
Net cash position 2024 * | 528M | Net cash position 2025 * | 356M | EV / Sales 2025 * | 179 x |
P/E ratio 2024 * |
-4.18
x | P/E ratio 2025 * |
-3.17
x | Employees | 124 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.74% |
Latest transcript on Zentalis Pharmaceuticals, Inc.
1 day | -0.68% | ||
1 week | -5.20% | ||
Current month | +5.52% | ||
1 month | -12.98% | ||
3 months | -2.34% | ||
6 months | -0.60% | ||
Current year | -22.97% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 20-06-30 | |
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 22-10-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Karan Takhar
BRD | Director/Board Member | 32 | 17-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.07% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 11.67 | -0.68% | 504,707 |
24-05-13 | 11.75 | -6.30% | 665,954 |
24-05-10 | 12.54 | +0.16% | 620,927 |
24-05-09 | 12.52 | +0.72% | 592,439 |
24-05-08 | 12.43 | +0.97% | 1,022,881 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.97% | 834M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- ZNTL Stock